A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, Kumar S.
Visram A, et al. Among authors: gertz ma.
Am J Hematol. 2023 Aug;98(8):1277-1285. doi: 10.1002/ajh.26990. Epub 2023 Jun 19.
Am J Hematol. 2023.
PMID: 37334773
Free article.
Clinical Trial.